According to Novartis' announcement, APPLAUSE-IgAN randomized Phase III trial results have provided positive final results showing that Fabhalta (iptacopan) was demonstrated to significantly slow decline in kidney function in adults with IgA...
.png)
AstraZeneca's Imfinzi (durvalumab) has demonstrated a significant increase in survival for early-stage gastric (GC) and gastroesophageal junction cancers (GEJC), according to new data from the European Society for Medical Oncology (ESMO) 2025...
Biocon Biologics Ltd (BBL) has reached significant achievement with Health Canada's approval of Yesintek (ustekinumab injection) and Yesintek IV, which are biosimilars of Stelara and Stelara IV. The Notice of Compliance was issued on...
Johnson & Johnson announced impressive outcomes for a subcutaneous formulation of amivantamab (Rybrevant) which achieved a 45% overall response rate (ORR) in individuals with advanced head and neck squamous cell carcinoma (HNSCC)...
Novartis announced that Cosentyx met its primary endpoint and all secondary endpoints in the Phase III REPLENISH study, a significant milestone in the treatment of polymyalgia rheumatica. At Week 52, Cosentyx demonstrated statistically...
Pfizer Inc. publicly released updated outcomes from the Phase 2 PHAROS trial examining Braftovi (encorafenib) + Mektovi (binimetinib) in adult subjects with metastatic non-small cell lung cancer (mNSCLC) harboring the BRAF V600E mutation...
Eli Lilly and Company has announced strong Phase 3 data for its investigational oral GLP-1 therapy Orforglipron from ACHIEVE-2 and ACHIEVE-5 trials, which could potentially lay the groundwork for a new treatment standard in type 2 diabetes...
On Monday AbbVie proclaimed that its newest arthritis medication, Rinvoq, outperformed the company’s established best-selling product Humira in a head-to-head clinical study. These findings represent a substantial achievement for AbbVie as it...
Novo Nordisk has made a significant advance in the rare disease sector by signing a definitive asset purchase and license agreement with Omeros Corporation to acquire its clinical-stage MASP-3 inhibitor zaltenibart...
.jpeg){kind=spacer}
CDSCO has given approval to Reliance Life Sciences Pvt. Ltd. for conducting a Phase I/III clinical trial of its biosimilar Nivolumab (R-TPR-067, RLS-Nivolumab). The approval is subsequent to the Subject Expert Committee (Oncology).
.jpg)
.jpg)
, CDSCO.jpg)